EP Patent

EP4536207A1 — Combinations of rxfp1 modulators and sglt2 inhibitors

Assigned to AstraZeneca AB · Expires 2025-04-16 · 1y expired

What this patent protects

The specification generally relates to combinations of RXFP1 modulators and SGLT2 inhibitors, in particular pharmaceutical compositions comprising such combinations, and therapeutic methods using such combinations.

USPTO Abstract

The specification generally relates to combinations of RXFP1 modulators and SGLT2 inhibitors, in particular pharmaceutical compositions comprising such combinations, and therapeutic methods using such combinations.

Drugs covered by this patent

Patent Metadata

Patent number
EP4536207A1
Jurisdiction
EP
Classification
—
Expires
2025-04-16
Drug substance claim
No
Drug product claim
No
Assignee
AstraZeneca AB
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.